PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 9, 20260 citationsOpen Access

Patient Priority of Proposed U.S. Bills for Physical AI Oncology Clinical Trials

View Full Paper
KKKevin Kawchak

Key Points

  • The aim is to prioritize cancer patients in U.S. oncology clinical trials through legal support for their autonomy.
  • Proposed U.S. bills HR 9501 to HR 9507 outline legal changes for patient engagement in clinical trials.
  • Emphasis on patient control over trial aspects like enrollment, scheduling, and data management.
  • Focus on the incorporation of advanced AI and robotics in enhancing patient autonomy.
  • Patients gain direct control over discovery and scheduling and maintain custody of their health data.
  • Proposed legislation supports a framework that prioritizes patient preferences in clinical trial participation.

Abstract

The cancer patient, not the doctor, the nurse, the trial sponsor, the IRB, or the regulator, is the priority participant in any United States oncology clinical trial. Advanced AI and advanced robotics now offer the patient direct control over discovery, enrollment, scheduling, robot selection, procedural modification, real-time data feedback, and self-custody of health data. Proposed bills HR 9501 through HR 9507 supply the legal infrastructure for that control.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Kevin Kawchak (2026) studied this question.

synapsesocial.com/papers/69fed140b9154b0b82878753https://doi.org/10.5281/zenodo.20045456
Ask AI
Helpful
Bookmark
Share
View Full Paper